

**Treatment-Experienced patients With Prior Null Response
All Patients**

TABLE 117: SVR GENOTYPE 1 TREATMENT-EXPERIENCED WITH PRIOR NULL RESPONSE: RELATIVE RISKS AND RISK DIFFERENCE FOR ALL TREATMENT COMPARISONS — RANDOM EFFECTS MODEL

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
SIM12 + SOF12	PR48	1.21 (0.19 to 3.58)	3.59 (−14.65 to 46.12)
T12 PR48 q8		1.53 (0.34 to 2.92)	9.54 (−11.13 to 30.64)
SOF12 + PR12		0.56 (0.06 to 2.83)	−7.47 (−18.99 to 31.75)
SIM12 PR48		1.67 (0.46 to 3.10)	12.28 (−9.33 to 32.19)
SOF12+ SIM12 + RBV12		2.44 (0.35 to 5.27)	25.58 (−10.83 to 68.67)
SOF12 + LDV12 + RBV12		3.77 (0.97 to 6.21)	51.31 (−0.49 to 74.94)
SOF12 + RBV12		0.73 (0.10 to 3.30)	−4.67 (−18.36 to 36.15)
PAR/RIT12 + OMB12 + DAS12		4.33 (1.09 to 6.86)	63.43 (1.34 to 80.38)
PAR/RIT12 + OMB12 + DAS12 + RBV12		4.51 (1.33 to 7.00)	67.00 (5.28 to 80.14)
DCV24 + ASU24		3.67 (1.32 to 5.78)	49.97 (5.00 to 67.75)
DCV24 + ASU24 + PR24	SIM12 + SOF12	4.16 (1.12 to 6.57)	60.54 (1.81 to 77.44)
T12 PR48 q8		1.18 (0.25 to 6.99)	3.42 (−35.75 to 31.84)
SOF12 + PR12		0.47 (0.09 to 2.84)	−9.60 (−41.69 to 18.99)
SIM12 PR48		1.31 (0.31 to 8.75)	6.03 (−35.09 to 35.56)
SOF12 + SIM12 + RBV12		1.81 (0.52 to 7.84)	17.63 (−12.86 to 57.35)
SOF12 + LDV12 + RBV12		2.90 (0.71 to 18.88)	41.49 (−9.91 to 78.62)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
SOF12 + RBV12		0.61 (0.07 to 7.14)	-7.02 (-52.88 to 36.78)
PAR/RIT12 + OMB12 + DAS12		3.35 (0.83 to 21.80)	52.48 (-5.17 to 84.94)
PAR/RIT12 + OMB12 + DAS12 + RBV12		3.53 (0.98 to 22.23)	55.82 (-0.60 to 86.09)
DCV24 + ASU24		2.91 (0.86 to 18.25)	40.34 (-5.84 to 71.79)
DCV24 + ASU24 + PR24		3.20 (0.94 to 18.16)	48.29 (-1.57 to 80.56)
SOF12 + PR12	T12 PR48 q8	0.39 (0.04 to 3.40)	-14.53 (-41.15 to 27.27)
SIM12 PR48		1.04 (0.46 to 3.82)	1.08 (-16.26 to 26.53)
SOF12+ SIM12 + RBV12		1.61 (0.27 to 7.48)	15.90 (-23.53 to 62.02)
SOF12 + LDV12 + RBV12		2.32 (1.15 to 7.54)	39.00 (2.50 to 65.73)
SOF12 + RBV12		0.51 (0.07 to 4.47)	-12.08 (-41.15 to 34.67)
PAR/RIT12 + OMB12 + DAS12		2.65 (1.27 to 9.25)	49.42 (4.13 to 74.46)
PAR/RIT12 + OMB12 + DAS12 + RBV12		2.77 (1.31 to 10.97)	52.54 (5.66 to 77.01)
DCV24 + ASU24		2.29 (1.44 to 7.60)	37.01 (8.62 to 59.22)
DCV24 + ASU24 + PR24		2.57 (1.28 to 8.25)	47.39 (4.42 to 67.71)
SIM12 PR48	SOF12 + PR12	2.83 (0.38 to 26.96)	17.20 (-23.28 to 42.28)
SOF12 + SIM12 + RBV12		3.96 (0.51 to 31.50)	29.53 (-13.04 to 74.21)
SOF12 + LDV12 + RBV12		6.33 (0.86 to 61.32)	54.70 (-3.77 to 86.06)
SOF12 + RBV12		1.28 (0.10 to 20.03)	2.25 (-37.40 to 44.10)
PAR/RIT12 + OMB12 + DAS12		7.31 (0.99 to 70.43)	66.17 (-0.18 to 91.41)
PAR/RIT12 + OMB12 + DAS12 + RBV12		7.72 (1.15 to 72.18)	69.74 (3.99 to 91.55)
DCV24 + ASU24		6.36 (1.00 to 59.63)	53.61 (-0.01 to 78.48)
DCV24 + ASU24 + PR24		6.93 (1.05 to 63.00)	62.49 (1.21 to 88.76)
SOF12+ SIM12 + RBV12	SIM12 PR48	1.49 (0.22 to 5.88)	13.97 (-28.49 to 60.10)
SOF12 + LDV12 + RBV12		2.20 (0.68 to 6.82)	37.90 (-8.95 to 66.41)
SOF12 + RBV12		0.46 (0.06 to 3.37)	-14.65 (-41.95 to 31.37)
PAR/RIT12 + OMB12 + DAS12		2.51 (0.80 to 7.79)	49.02 (-4.90 to 73.93)
PAR/RIT12 + OMB12 + DAS12 + RBV12		2.62 (1.17 to 7.01)	51.94 (3.63 to 70.70)
DCV24 + ASU24		2.15 (0.88 to 6.74)	36.17 (-3.55 to 60.91)
DCV24 + ASU24 + PR24		2.43 (0.77 to 7.19)	46.77 (-6.09 to 68.65)
SOF12 + LDV12 + RBV12	SOF12 + SIM12 + RBV12	1.46 (0.38 to 9.97)	20.20 (-37.45 to 71.32)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
SOF12 + RBV12		0.32 (0.04 to 3.55)	-26.93 (-76.77 to 26.09)
PAR/RIT12 + OMB12 + DAS12		1.70 (0.45 to 11.33)	30.67 (-31.24 to 78.68)
PAR/RIT12 + OMB12 + DAS12 + RBV12		1.77 (0.54 to 11.72)	33.94 (-25.84 to 79.57)
DCV24 + ASU24		1.46 (0.49 to 9.75)	19.97 (-32.36 to 64.17)
DCV24 + ASU24 + PR24		1.62 (0.47 to 10.20)	27.28 (-30.11 to 74.13)
SOF12 + RBV12	SOF12 + LDV12 + RBV12	0.21 (0.03 to 1.51)	-52.25 (-84.90 to 11.70)
PAR/RIT12 + OMB12 + DAS12		1.13 (0.38 to 3.49)	9.51 (-39.16 to 54.32)
PAR/RIT12 + OMB12 + DAS12 + RBV12		1.17 (0.44 to 3.87)	12.27 (-36.70 to 57.91)
DCV24 + ASU24		0.97 (0.43 to 3.03)	-2.37 (-38.64 to 40.53)
DCV24 + ASU24 + PR24		1.10 (0.38 to 3.25)	7.02 (-41.44 to 47.13)
PAR/RIT12 + OMB12 + DAS12	SOF12 + RBV12	5.55 (0.81 to 40.76)	63.76 (-5.60 to 90.71)
PAR/RIT12 + OMB12 + DAS12 + RBV12		5.86 (0.92 to 42.53)	67.06 (-2.42 to 90.59)
DCV24 + ASU24		4.78 (0.84 to 34.61)	50.89 (-6.39 to 78.44)
DCV24 + ASU24 + PR24		5.32 (0.78 to 39.03)	60.17 (-7.49 to 88.07)
PAR/RIT12 + OMB12 + DAS12 + RBV12	PAR/RIT12 + OMB12 + DAS12	1.03 (0.38 to 3.23)	2.29 (-44.71 to 51.99)
DCV24 + ASU24		0.85 (0.37 to 2.66)	-12.33 (-48.41 to 35.61)
DCV24 + ASU24 + PR24		0.98 (0.32 to 2.78)	-2.10 (-50.23 to 41.58)
DCV24 + ASU24	PAR/RIT12 + OMB12 + DAS12 + RBV12	0.82 (0.34 to 2.29)	-15.21 (-51.17 to 32.92)
DCV24 + ASU24 + PR24		0.95 (0.30 to 2.36)	-4.16 (-54.12 to 37.81)
DCV24 + ASU24 + PR24	DCV24 + ASU24	1.14 (0.37 to 2.44)	10.16 (-37.13 to 40.77)
Random effect model	Residual deviance	35.61 vs. 34 data points	
	Deviance information criteria	188.092	
Fixed effect model	Residual deviance	32.86 vs. 34 data points	
	Deviance information criteria	182.925	

ASU = asunaprevir; Crl = credible interval; DAS = dasabuvir; DCV = daclatasvir; ELB = elbasvir; LDV = ledipasvir; OMB = ombitasvir; PAR = paritaprevir; PR = pegylated interferon plus ribavirin; q8 = every 8 hours; RBV = ribavirin; RD = risk difference; RGT = response-guided therapy; RIT = ritonavir; RR = relative risk; SIM = simeprevir; SOF = sofosbuvir; SVR = sustained virologic response; T = telaprevir; vs. = versus.

Note: Please refer to Treatment Regimen Nomenclature table for description of dosages.